Pathstone Holdings LLC Decreases Holdings in Humana Inc. (NYSE:HUM)

Pathstone Holdings LLC lessened its stake in shares of Humana Inc. (NYSE:HUM) by 9.4% in the 3rd quarter, Holdings Channel reports. The firm owned 16,608 shares of the insurance provider’s stock after selling 1,727 shares during the period. Pathstone Holdings LLC’s holdings in Humana were worth $5,265,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Mendota Financial Group LLC raised its holdings in shares of Humana by 9.2% during the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 27 shares during the last quarter. Capital Advisors Ltd. LLC raised its stake in Humana by 17.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after purchasing an additional 31 shares during the last quarter. CarsonAllaria Wealth Management Ltd. lifted its holdings in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares in the last quarter. Harbour Investments Inc. boosted its stake in Humana by 10.5% during the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock worth $161,000 after purchasing an additional 41 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft grew its holdings in shares of Humana by 1.0% during the second quarter. Baader Bank Aktiengesellschaft now owns 4,421 shares of the insurance provider’s stock worth $1,649,000 after buying an additional 42 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Up 0.8 %

Shares of NYSE:HUM opened at $298.11 on Friday. The firm has a market capitalization of $35.90 billion, a PE ratio of 26.40, a price-to-earnings-growth ratio of 2.19 and a beta of 0.52. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $527.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm’s 50-day moving average is $276.83 and its two-hundred day moving average is $330.64.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Analysts predict that Humana Inc. will post 15.86 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.19%. Humana’s payout ratio is 31.36%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on HUM shares. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Cantor Fitzgerald restated a “neutral” rating and set a $395.00 target price on shares of Humana in a report on Tuesday, October 1st. Jefferies Financial Group cut Humana from a “buy” rating to a “hold” rating and cut their price target for the company from $519.00 to $253.00 in a report on Monday, October 7th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Finally, Oppenheimer reduced their price target on Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a report on Thursday, October 3rd. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.